Project Grant R01EB034692

Award Date 7/15/24
Completion Date 4/30/28
Dollars Obligated $867K
Federal Grant Program
93.286
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $235,707 to Weill Medical College of Cornell University to conduct research on the use of [68Ga]-DOTATATE PET/MRI imaging to improve diagnostic accuracy, increase understanding of pituitary neuroendocrine tumor (PitNET) biology, and optimize stereotactic radiosurgery (SRS) targeting for residual/recurrent PitNET. The research aims to characterize the range of...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $616,033 to the University of California, Davis to develop and validate a PET-enabled dual-energy CT (DECT) imaging method. The goal is to create a technique that can derive a high-energy gamma-ray CT (GCT) image from standard PET/CT emission data, and combine it with...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,361 to Yale University to develop deep learning-based predictive models for personalizing dosimetry and treatment planning for prostate cancer patients receiving 177Lu-PSMA radiopharmaceutical therapy (RPT). The key products and services to be delivered include: Building predictive models using pre-treatment PSMA-PET and during-treatment PSMA-SPECT imaging data, as well as clinical...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
The Regents of the University of Colorado, doing business as the University of Colorado-Denver, received a $388,467 Project Grant award from the National Cancer Institute under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an automated, generalizable lesion detection system called GELES for positron emission tomography-computed tomography (PET/CT) imaging of gastroenteropancreatic neuroendocrine tumors. The two-year project aims to create deep...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $666,670 to The Trustees of the University of Pennsylvania to develop innovative scan protocols that combine long axial field-of-view PET and spectral CT imaging for improved quantification in oncology. The goal is to create methods and protocols to obtain high-quality dynamic information from both PET and CT modalities, and to use dynamic spectral CT for PET...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) provides $597,766 to The Trustees of the University of Pennsylvania to develop novel methods for dual-tracer PET imaging to better characterize cancer. The key objectives are to: 1) Develop protocols to image fluoroglutamine and FDG in breast cancer patients using a long-axial field-of-view PET scanner to enable quantitative analysis of tumor metabolism, and 2) Develop...
The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
This federal Project Grant award of $402,728 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop innovative interpretable deep learning models for multi-modality imaging in cancer prognostic assessment, with a focus on improving the accuracy and interpretability of prognosis predictions for gastric cancer patients. The funded research project at Wake Forest University Health Sciences will integrate domain knowledge from physician...

DEEP LEARNING METHODS FOR IMPROVING GALLIUM 68-BASED PET IMAGING - ABSTRACT NEUROENDOCRINE TUMORS (NETS) ARE A HETEROGENEOUS GROUP OF TUMORS WITH INCREASING INCIDENCE, WHICH ARE HARD TO IDENTIFY IN THE EARLY STAGE AND REPEATEDLY MISDIAGNOSED, YIELDING 20%-50% OF PATIENTS WITH DISTANT METASTASES AT INITIAL DIAGNOSIS. PROSTATE CANCER (PCA) IS THE MOST COMMON SOLID-ORGAN MALIGNANCY IN MEN IN THE UNITED STATES. DISTINGUISHING INDOLENT FROM AGGRESSIVE PCA AND DIFFERENTIATION OF LOCALIZED DISEASE AND METASTATIC SPREAD ARE ESSENTIAL FOR PCA TREATMENT SELECTION. FOR BOTH NETS AND PCA, DISEASE-SPECIFIC OVEREXPRESSION EXISTS IN CANCER CELLS. 68GA-DOTATATE AND 68GA-PSMA-11, THE TWO MOST WIDELY USED GALLIUM-68 PET TRACERS, CAN TARGET THE OVEREXPRESSION IN CANCER CELLS OF NETS AND PCA, RESPECTIVELY. THEY ARE ESSENTIAL IMAGING TECHNIQUES FOR NETS AND PCA MANAGEMENT, GIVEN THEIR HIGH SENSITIVITY AND SPECIFICITY IN DETECTING PRIMARY TUMOR AND METASTATIC SPREAD. DUE TO THE SHORTER HALF-LIFE AND LARGER POSITRON RANGE OF GALLIUM 68 AND THE LOWER INJECTION DOSE LIMITED BY GENERATOR CAPACITY, GALLIUM-68 PET HAS A LOWER IMAGE QUALITY COMPARED WITH 18F-FDG PET, WHICH SIGNIFICANTLY COMPROMISES ITS LESION DETECTABILITY AND QUANTIFICATION ACCURACY. AS GALLIUM-68 PET IS INCREASINGLY ADOPTED IN CLINICS, THERE ARE UNMET NEEDS TO FURTHER OPTIMIZE IT FOR BETTER DISEASE MANAGEMENT. THE GOAL OF THIS PROJECT IS TO IMPROVE GALLIUM 68-BASED PET IMAGE QUALITY THROUGH DEEP LEARNING (DL)-BASED MOTION CORRECTION, IMAGE RECONSTRUCTION, AND KINETIC MODELING. AIM 1 OF THIS PROJECT IS TO DEVELOP A DATA-DRIVEN RESPIRATORY MOTION-CORRECTION FRAMEWORK WITH PHASE-MATCHED ATTENUATION CORRECTION. AIM 2 OF THIS PROJECT IS TO DEVELOP A DL-BASED IMAGE RECONSTRUCTION METHOD TO IMPROVE STATIC GALLIUM 68-BASED PET IMAGING. AIM 3 OF THIS PROJECT IS TO FURTHER DEVELOP DL-BASED KINETIC-MODELING METHODS TO IMPROVE DYNAMIC GALLIUM 68-BASED PET IMAGING. AIM 4 OF THIS STUDY IS TO PERFORM COMPREHENSIVE CLINICAL EVALUATIONS OF THE DEVELOPED METHODS. WE EXPECT THAT THE INTEGRATED OUTCOME OF THE FOUR AIMS WILL BE NOVEL, EFFECTIVE, AND ROBUST MOTION CORRECTION AND RECONSTRUCTION METHODS FOR GALLIUM-68 PET THAT CAN IMPROVE ITS LESION DETECTABILITY AND QUANTIFICATION ACCURACY.

Posted 7/11/24, 12:00 AM